铂耐药卵巢癌的免疫疗法：一线希望

Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope.

作者信息

Brancewicz Jan, Padzińska-Pruszyńska Irena Barbara, Kubiak Małgorzata, Kucharzewska Paulina

机构信息

Cellis AG, Bleicherweg 45, 8002 Zurich, Switzerland.

Center of Cellular Immunotherapies, Warsaw University of Life Sciences, Building 23, Level 0, Laboratory Number 0135, 8 Ciszewskiego St., 02-786 Warsaw, Poland.

出版信息

Cells. 2025 Jun 29;14(13):995. doi: 10.3390/cells14130995.

DOI:10.3390/cells14130995

PMID:40643516

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12248509/

Abstract

Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.

摘要

卵巢癌是女性癌症相关死亡的主要原因之一，铂耐药性构成了重大挑战。在这些病例中，传统疗法往往失败，凸显了对新型治疗方法的迫切需求。免疫疗法已成为一种有前景的策略，为铂耐药性卵巢癌（PROC）患者带来了新的希望。本综述探讨了PROC免疫疗法的当前状况，讨论了不同的方法、它们的作用机制以及克服传统治疗局限性的潜力。